Plus Therapeutics Announces Validation & Clinical Implementation of CSF-01 Leptomeningeal Cancer Cell Diagnostic

Plus’ CSF-01 cancer cell enumeration test is a sensitive and specific diagnostic test for the presence of adenocarcinoma and melanoma cancer cells in the leptomeninges CSF-01 testing is used as an exploratory endpoint in the ReSPECT-LM trials Controlled clinical trial data evaluating the utility of CSF-01 in clinical decision-making is anticipated to be released in Q2/Q3 2024 AUSTIN, Texas, March 25, 2024 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stag

Related Keywords

Houston ,Texas ,United States ,San Francisco ,California ,San Antonio ,Corey Davis ,March Hedrick ,Priya Kumthekar ,Us National Institutes Of Health ,Nasdaq ,Northwestern University ,Clinical Laboratory Improvement Amendments ,Research Institute Of Texas ,National Cancer Institute ,Therapeutics Inc ,Feinberg School Of Medicine ,Cancer Prevention Research Institute Of Texas ,Associate Professor ,Feinberg School ,Cancer Prevention ,Research Institute ,Leptomeningeal Metastases ,Plus Therapeutic ,Plus Therapeutics ,Clinical Trials ,Sf ,The Company ,Central Nervous System ,Company ,Cancers ,Pharmaceutical Company ,Clinical Development ,Breast Cancer ,Rhenium ,Lung Cancer ,